Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Primary research

EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells

Authors: Yingdong Zhang, Junjie Wang, Feng Liu, Zhenyu You, Ruijie Yang, Yong Zhao

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Background

The purpose of the present study is to investigate the direct biological effects of the epidermal growth factor receptor (EGFR) inhibitor C225 on the radiosensitivity of human lung squamous cancer cell-H520. H520 cells were treated with different dosage of 60Co γ ray irradiation (1.953 Gy/min) in the presence or absence of C225. The cellular proliferation, colony forming capacity, apoptosis, the cell cycle distribution as well as caspase-3 were analyzed in vitro.

Results

We found that C225 treatment significantly increased radiosensitivity of H-520 cells to irradiation, and led to cell cycle arrest in G1 phase, whereas 60Co γ ray irradiation mainly caused G2 phase arrest. H-520 cells thus displayed both the G1 and G2 phase arrest upon treatment with C225 in combination with 60Co γ ray irradiation. Moreover, C225 treatment significantly increased the apoptosis percentage of H-520 cells (13.91% ± 1.88%) compared with the control group (5.75% ± 0.64%, P < 0.05).

Conclusion

In this regard, C225 treatment may make H-520 cells more sensitive to irradiation through the enhancement of caspase-3 mediated tumor cell apoptosis and cell cycle arrest.
Appendix
Available only for authorised users
Literature
1.
Ray M, Salgia R, Vokes EE: The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009, 14: 1116-1130. 10.1634/theoncologist.2009-0054.CrossRefPubMed
2.
Rosell R, Moran T, Carcereny E, Quiroga V, Molina MA, Costa C, Benlloch S, Taron M: Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol. 2010, 12: 75-80. 10.1007/S12094-010-0473-0.CrossRefPubMed
3.
Paz-Ares L, Soulieres D, Melezinek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B: Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2010, 14: 51-69. 10.1111/j.1582-4934.2009.00991.x.PubMedCentralCrossRefPubMed
4.
Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T, Ono M: Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010, 16 (12): 3163-10.1158/1078-0432.CCR-09-3239.CrossRefPubMed
5.
Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W, Wang Y, Jin G, Ma H, Zhang M, Hu Z, Shen H: Polymorphisms in EGFR and VEGF contribute to non-small cell lung cancer survival in a Chinese Population. Carcinogenesis. 2010, 31 (6): 1080-1086. 10.1093/carcin/bgq079.CrossRefPubMed
6.
Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA: New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010, 69 (1): 1-12. 10.1016/j.lungcan.2009.12.009.CrossRefPubMed
7.
Chen CC, Chiu HH, Yen LC, Chang HJ, Chang MS, Tsai JR, Chen YF, Lin SR: Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. Oncol Rep. 2010, 23: 639-645.PubMed
8.
Baumann M, Krause M: Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol. 2004, 72: 257-266. 10.1016/j.radonc.2004.07.007.CrossRefPubMed
9.
Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res. 2003, 9: 2316-2326.PubMed
10.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422.CrossRefPubMed
11.
Zhang J, Ji J, Yuan F, Ma T, Ye ZB, Yu YY, Liu BY, Zhu ZG: [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism]. Zhonghua Zhong Liu Za Zhi. 2009, 31: 85-89.PubMed
12.
Kies MS, Harari PM: Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Curr Opin Investig Drugs. 2002, 3: 1092-1100.PubMed
13.
Bernier J, Schneider D: Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?. Eur J Cancer. 2007, 43: 35-45. 10.1016/j.ejca.2006.08.035.CrossRefPubMed
14.
Kim ES, Vokes EE, Kies MS: Cetuximab in cancers of the lung and head & neck. Semin Oncol. 2004, 31: 61-67. 10.1053/j.seminoncol.2003.12.016.CrossRefPubMed
15.
Bernier J: Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006, 6: 1539-1552. 10.1586/14737140.6.11.1539.CrossRefPubMed
16.
Liao HJ, Carpenter G: Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 2009, 69: 6179-6183. 10.1158/0008-5472.CAN-09-0049.PubMedCentralCrossRefPubMed
17.
Le Tourneau C, Siu LL: Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol. 2008, 20: 256-263. 10.1097/CCO.0b013e3282f9b575.CrossRefPubMed
18.
Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP: Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol. 2002, 12: 11-20. 10.1053/srao.2002.34864.CrossRefPubMed
19.
Dy GK, Adjei AA: Novel targets for lung cancer therapy: part I. J Clin Oncol. 2002, 20: 2881-2894. 10.1200/JCO.2002.11.145.CrossRefPubMed
20.
Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Baron AE, Zeng C, Johnson TK, Bunn PA: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005, 11: 795-805.PubMed
21.
Harari PM, Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001, 49: 427-433. 10.1016/S0360-3016(00)01488-7.CrossRefPubMed
22.
Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer. Cancer Biol Ther. 2004, 3: 490-
23.
Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA: EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008, 19: 1053-1059. 10.1093/annonc/mdn006.CrossRefPubMed
24.
Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Molecular biology of the cell. 1999, 10: 2493-2506.PubMedCentralCrossRefPubMed
25.
Hagan M, Yacoub A, Dent P: Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res. 2004, 10: 5724-5731. 10.1158/1078-0432.CCR-04-0420.CrossRefPubMed
26.
Geldof AA, Plaizier MA, Duivenvoorden I, Ringelberg M, Versteegh RT, Newling DW, Teule GJ: Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol. 2003, 129: 175-182.PubMed
27.
Fan QW, Weiss WA: RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene. 2005, 24: 829-837. 10.1038/sj.onc.1208227.CrossRefPubMed
28.
Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL, Lee SB: EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res. 2010, 70: 1154-1163. 10.1158/0008-5472.CAN-09-1993.PubMedCentralCrossRefPubMed
Metadata
Title
EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells
Authors
Yingdong Zhang
Junjie Wang
Feng Liu
Zhenyu You
Ruijie Yang
Yong Zhao
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-39

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Primary research

Tumour suppressor function of MDA-7/IL-24 in human breast cancer

Primary research

Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases

Primary research

Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells

Primary research

ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target

Primary research

Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis.

Primary research

CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits